BD to Present at Barclays 28th Annual Global Healthcare Conference
Rhea-AI Summary
BD (NYSE: BDX) will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026 at 8:30 a.m. ET. The presentation will be webcast live and a replay will be posted on BD's investor relations website, investors.bd.com.
Positive
- None.
Negative
- None.
News Market Reaction – BDX
In the Feb 24 session, BDX declined 1.00%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Leadership appointment | Positive | -0.1% | Named new executive vice president and general counsel joining leadership team. |
| Feb 10 | Debt tender offers | Neutral | -17.2% | Launched tender offers to repurchase up to $1.6B of senior notes. |
| Feb 09 | Waters combination | Positive | -1.3% | Completed spin-off and cash-plus-stock combination of key businesses with Waters. |
| Feb 09 | Waters transaction | Positive | -1.3% | Waters closed combination with BD units via Reverse Morris Trust structure. |
| Feb 09 | Earnings release | Neutral | -1.3% | Reported Q1 FY2026 results and affirmed full-year New BD guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent strategic and financial announcements, including the Waters combination and large debt tender offer, have generally been followed by negative price reactions, even when the news was constructive or neutral.
Over recent months, BD has reported Q1 FY2026 results, completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters, and launched tender offers for up to $1.6 billion of debt. These actions reshape the portfolio and balance sheet, while leadership changes, such as appointing a new general counsel, support execution. Despite these developments, shares showed mostly negative one-day reactions, framing today’s conference participation within a period of strategic transition and cautious market response.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 8:30 am Eastern Time.
The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors: |
Matt Marcus | Shawn Bevec SVP, Investor Relations |
View original content:https://www.prnewswire.com/news-releases/bd-to-present-at-barclays-28th-annual-global-healthcare-conference-302694898.html
SOURCE BD (Becton, Dickinson and Company)